CN1869064A - Tumour antigen protein and tumour antigen peptide - Google Patents
Tumour antigen protein and tumour antigen peptide Download PDFInfo
- Publication number
- CN1869064A CN1869064A CN 200510011816 CN200510011816A CN1869064A CN 1869064 A CN1869064 A CN 1869064A CN 200510011816 CN200510011816 CN 200510011816 CN 200510011816 A CN200510011816 A CN 200510011816A CN 1869064 A CN1869064 A CN 1869064A
- Authority
- CN
- China
- Prior art keywords
- ser
- tumor antigen
- tumour
- sequence
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A tumor antigen protein and its tumor antigen peptide used to prepare the medicine for treating lung cancer are disclosed. Said tumor antigen protein can generate the peptide fragment by cell endolysis. Said peptide fragment can bind with the (MHC)-I molecular compatible with main tissue and can be recognized by T cells. The DNA sequence coding said tumor antigen protein has the nucleotide sequence No.AF497803 in GenBank.
Description
Technical field
The present invention relates to a kind of tumour specific antigen protein and tumor antigen peptide, particularly relate to a kind of tumor antigen protein matter and tumor antigen peptide that is used for the treatment of lung cancer.
Background technology
The biotherapy of tumour day by day becomes irreplaceable important component part in the combined therapy of tumour as the new model of oncotherapy, and it has mainly comprised immunotherapy and gene therapy two aspects.From the trend analysis of present international research, infer that from angle of practical application the immunotherapy of tumour will have wide practical use.Traditional method is to make antigen with tumour cell, tumor extract or a certain composition to inoculate to the patient, reaches the purpose of control tumour by challenge.Yet, can not determine under the situation of tumour specific antigen that the non-specific immunity activity that is caused is very limited aspect the control tumor growth.
In nineteen fifties, people such as Foley self the tumour cell immunity of the mouse that produces tumour through chemomorphosis with deactivation after, the tumour cell of living for this mouse inoculation again, these tumour cells are ostracised and can not be grown into tumour, mouse then survives; And behind the tumour cell that the inoculation of self tumour cell mice immunized of deactivation useless is lived, tumour cell is not ostracised and is grown into tumour, and mouse is then dead.This experiment has proved that with compellent evidence there is tumour specific antigen in the tumour of chemomorphosis; but this protective reaction has accurate specificity; promptly only at the tumour of same type and not at different types of tumors, even to also not having provide protection with same carcinogen dissimilar tumours of inductive on same mouse.Therefore, seek tumour specific antigen, thereby the development work of the vaccine of further being correlated with is basic, essential.
The tumour antigen kind is more, and characteristic differs.A wherein important class is the tumour antigen that can be discerned by specific CTL.As the class oncoprotein, wherein most typical is proto-oncogene HER-2/neu, and this gene also has expression in healthy tissues, wants high 100～200 times but express in tumor tissues, and its corresponding antigens peptide activates specific CTL in occupation of most of MHC I quasi-molecules.What in addition, using value arranged more is tumor cells expression antigen.This class antigen is mainly at tumor cells expression, and healthy tissues is not expressed, and is a kind of tumour antigen that CTL identification is arranged of understanding early as the Saliva Orthana of tumor cell surface.Because it is not expressed in healthy tissues, and only in the characteristic of expression of tumor tissue, makes that its side effect is littler, target is stronger, has more wide prospect in antitumor application.
Think that at present the generation of tumour fundamentally can be summed up as the unusual of a series of tumor-related gene 26S Proteasome Structure and Functions, tumour antigen promptly is expressed some albumen unusual on quality and quantity or polypeptide of these aberrant genes.The antineoplastic immune of body is mainly finished by cellular immunization.Along with the understanding of people to immune response essence, it is found that no matter how complicated the process of immunne response is, finally cause the T cell activation and produce being exactly to combine and forming antigenic peptide complexes and costimulatory signal of lethal effect with major histocompatibility complex MHC, that is: cytotoxic T cell (CTL) is by the TXi Baoshouti (TCR) on self surface, the complex body that recognition expression combines with major histocompatibility complex (MHC) I class antigen and forms in the tumor antigen protein matter/peptide of tumor cell surface, thus killing tumor cell attacked.
The generation of tumor antigen protein matter/peptide is to become tumour antigen by tumor cells expression, it is resolved into the antigen peptide of 8～10 amino acid sizes by various proteolytic enzyme in cell, the MHC I quasi-molecule that produces in these antigen peptide and the endoplasmic reticulum combines, be expressed in the surface of cell by Golgi complex, the final special CTL of tumour antigen that gives, thereby bring out immunne response, kill and wound the removing tumour cell.The proteantigen molecule that thisly be present in the tumour cell, can combine and bring out organism immune response with the MHC molecule is tumour antigen.Can only produce a immune response with these antigen induction bodies at tumour cell, thus the intravital tumour cell of specific killing and reach the effect that treatment or control tumour cell shift.
Lung cancer is common malignancy the most in the human tumor, and especially in the last few years, sickness rate increased gradually.At present, mainly be auxiliary treating methods such as traditional excision and chemicotherapy to the treatment of lung cancer, but, transfer has been arranged during discovery, so prognosis be still undesirable because most of patient has entered middle and advanced stage when making a definite diagnosis.Seek tumour specific antigen, and then carry out immunotherapy and will help the early diagnosis of lung cancer undoubtedly, and improve patient's prognosis.
Summary of the invention
The object of the present invention is to provide a kind of tumour specific antigen protein and tumor antigen peptide that can be used for lung cancer therapy.
The objective of the invention is to realize by the following technical solutions:
The invention provides a kind of tumour specific antigen protein, this protein is by decomposing in the cell, can produce the peptide fragment combine with major histocompatibility complex (MHC)-I quasi-molecule, can be discerned by the T cell, it has following (a) or (b) described aminoacid sequence:
(a) has the aminoacid sequence shown in the sequence 1;
(b) with the aminoacid sequence in (a) through the replacement of one or several amino-acid residue, disappearance or add the derived protein that sudden change is produced, and this derived protein has identical functions with (a) protein.
The invention provides a kind of dna sequence dna, its described tumor antigen protein matter of encoding.
Dna sequence dna of the present invention has the nucleotide sequence shown in the sequence 2, and accession number is in the gene library: BJ-TSA-9 AF497803.
The invention provides of the application of described protein as tumour specific antigen.
The invention provides of the application of described gene as the tumour specific antigen gene.
The invention provides the tumor antigen peptide of the peptide fragment same function that a kind of and described tumour specific antigen protein produced, it has the 164th～the 172nd aminoacid sequence of aminoacid sequence in the sequence 1.
The application of tumor antigen protein matter of the present invention in preparation treatment lung-cancer medicament.
The application of tumor antigen peptide of the present invention in preparation treatment lung-cancer medicament.
The advantage of tumour specific antigen protein provided by the invention and tumor antigen peptide is: the present invention finds first and successfully clones BJ-TSA-9, and is accredited as the tumour specific antigen gene; When using immunization method treatment cancer, can produce a immune response with these antigen induction bodies at tumour cell, do not killing and wounding the Normocellular while, the intravital tumour cell of specific killing reaches the effect of treatment or the transfer of control tumour cell; Simultaneously, can be by to this tumor antigen gene or detection of antibodies, to generation, the development of tumour and whether have to shift and diagnose.
Description of drawings
Fig. 1 is the RT-PCR detected result of the gene BJ-TSA-9 of code book invention antigen protein 16 kinds of adult's healthy tissuess; Among the figure 1～16 represents adult's healthy tissues spleen, prostate gland, ovary, small intestine, large intestine, white corpuscle, heart, lung, liver, brain, kidney, placenta, testis, skeletal muscle, pancreas, thymus gland respectively.P represents the positive control of PCR, and N represents negative control.
Fig. 2 is that the gene BJ-TSA-9 of code book invention antigen protein is the cancerous tissue of lung cancer and the RT-PCR result of paired cancer beside organism; Ca. among the figure represents cancerous tissue, and Adj. represents paired cancer beside organism.
Fig. 3 be BJ-TSA-9 in the Northern of cancerous lung tissue results of hybridization, wherein Ca. is a cancerous tissue, Adi. is a cancer beside organism.
Fig. 4 is the expression of recombinant proteins result of antigen protein of the present invention in the intestinal bacteria kind, and the Western blot result who identifies expression product.Wherein M is the molecular weight of albumen mark; 1 is the bacterial lysate before inducing, and 2 are the bacterial lysate after inducing; 3 is the supernatant behind the ultrasonic degradation, and 4 is the inclusion body behind the ultrasonic degradation; 4 is the Western blot of target protein behind the purifying, 5 negative contrasts.
Embodiment
By the following examples tumor antigen protein matter provided by the invention and tumor antigen peptide are carried out more detailed explanation.
The discovery of BJ-TSA-9 full-length cDNA in embodiment 1, the tumor tissues
According to Unigene among the Genbank and the data in the est database, use online information biology instrument such as SAGE and virtualNortherns, analyze the sequence on the karyomit(e) No. 8, found No. eight long-armed 24 districts of karyomit(e) tumour-specific gene of may encoding.So, from cancerous lung tissue, successfully clone the full length mRNA sequence of BJ-TSA-9 according to its sequences Design specific PCR primer.
At first extract lung cancer and the total RNA of cancer beside organism with TRIzol test kit (Gibco company), uv-spectrophotometric detects concentration and the purity of mRNA.Use advantage reverse transcriptase test kit (Clontech company) to carry out reverse transcription, with the synthetic cDNA of the total RNA of 2 μ g.After being diluted to 100ul, get 2.5ul, carry out PCR with high-fidelity pfu DNA synthetic enzyme as template, condition be 94 ℃ 20 seconds; 60 ℃ 30 seconds; 72 ℃ 1 minute 30 seconds, 35 circulations, 72 ℃ were extended 7 minutes again.Primer sequence is a forward: 5 '-CAC TTC TTG GAG GTG CCC TGCACG-3 '; Oppositely: 5 '-CTC CCA AGC CCA GCT TTC CAA AGG-3 '.PCR product 8 μ l analyze with 1% agarose gel electrophoresis, and use the Taq archaeal dna polymerase to add after the polyA tail, are cloned into pGEM-T Easy vector according to a conventional method, are transformed into competence E.coli TOP10F ' bacterium, serve the order-checking of sea base Kanggong department.The gained result carries out homology comparison with the nucleotide sequence among Blast software and the GenBank, and the sequence on result and No. eight karyomit(e) is identical.So far, we have successfully cloned the full cDNA of BJ-TSA-9 from cancerous lung tissue.Embodiment 2, prove the expression of BJ-TSA-9 gene in 16 kinds of healthy tissuess of people and lung cancer, intestinal cancer, cancer of the stomach with the method for RT-PCR
CDNA (the spleen of 16 kinds of commercial people's healthy tissuess of the CLONTECH of biotech company, prostate gland, testis, ovary, small intestine, large intestine, white corpuscle, heart, lung, liver, brain, kidney, pancreas, placenta, skeletal muscle, thymus gland), derive from the cancerous tissue of 40 routine lung cancer patients and the cDNA of paired cancer beside organism, derive from the cancerous tissue of 12 routine colon cancer patients and the cDNA of paired cancer beside organism, derive from the cancerous tissue of 10 routine Patients with Gastric Cancer and the cDNA of paired cancer beside organism and be used to detect the expression of BJ-TSA-9 gene at healthy tissues and tumor tissues.
Carry out the condition of RT-PCR among the present invention: use the advanced warm start archaeal dna polymerase of CLONTECH company, 94 ℃ 20 seconds; 64 ℃ 30 seconds; 72 ℃ 1 minute 30 seconds, 35 circulations, 72 ℃ were extended 7 minutes afterwards.Carry out the primer sequence of RT-PCR, forward: 5 '-CAC TTC TTG GAG GTG CCC TGC ACG-3 '; Oppositely: 5 '-CTC CCA AGC CCA GCT TTC CAA AGG-3 ' found that: in 16 kinds of important healthy tissuess of adult, the BJ-TSA-9 gene does not all have expression (as shown in Figure 1); The BJ-TSA-9 gene is expressed in the cancer of the stomach of 52% lung cancer, 33% intestinal cancer and 30%, and (as shown in Figure 2) do not expressed by paired cancer beside organism with it.Present embodiment proof tumour specific antigen gene BJ-TSA-9 expresses in a variety of cancerous tissue, and not having expression in healthy tissues, (accession number is in the gene library: AF497803) with its called after tumour-specific gene BJ-TSA-9 according to the present known character of this gene for we.
From the cancerous tissue of lung cancer patient and paired cancer beside organism, extract total RNA with TRIZOL reagent (PROMEGA), under the condition that methane amide, formaldehyde exist with total RNA sex change of 20ug, carry out forwarding on the Hybond-N+ nylon membrane (Amersham) after the agarose electrophoresis, fix with UV-crosslinked method.With the dna fragmentation of coming out that increases among digoxin dna probe labelling kit (ROCHE) the mark embodiment 2, to make dna probe, hybridize according to the Northern hybridizing method of routine and the tRNA on the film, carry out radioautograph afterwards, detect the mRNA of the tumour specific antigen protein gene BJ-TSA-9 among the present invention.Then, in 1%SDS solution, boil detecting the used film of this gene mRNA, remove the probe of digoxigenin labeled after, make probe with the house-keeping gene G3PDH of mark, use the same method and carry out Northern blot hybridization, detected mRNA makes positive control.The result shows that the mRNA of tumor antigen protein plasmagene of the present invention only expresses in the cancerous tissue of lung cancer, and (as shown in Figure 3) do not expressed by paired cancer beside organism, and this characteristic with the tumour specific antigen gene is consistent.
Use pET32a prokaryotic expression carrier (purchasing company) in INVOTRIGEN, the plasmid pET32a-BJ-TSA-9 of construction expression specific antigens BJ-TSA-9, this plasmid is in coli strain B121 (commentaries on classics has the intestinal bacteria rare codon) (purchasing the company in INVOTRIGEN), under 37 ℃ of growth conditionss, 1mM IPTG induced recombinant protein expression 6 hours.The SDS-PAGE protein electrophoresis is identified Recombinant Protein Expression.Afterwards, application of nickel ion affinity chromatography pillar (purchasing company) in INVOTRIGEN with recombinant protein from the intestinal bacteria whole protein, separate, purifying comes out.The monoclonal antibody (purchasing the company in INVOTRIGEN) of 6 Histidines that have with anti-recombinant protein by the Western hybridizing method, is identified (Fig. 4) to recombinant protein.The result has the albumen of expection on about 60kD position of expection size, the Western hybridization of carrying out with the monoclonal antibody of anti-six Histidines has confirmed that expressed proteins is exactly the recombinant protein of BJ-TSA-9 gene.
Formation and the CTL killing experiments in vitro of embodiment 5, the external evoked CTL of application tumor antigen peptide
With reference to the experimental technique in the Chinese general surgery magazine (17:218,2002).With 2 * 10
6The PBMC of/ml concentration (peripheral blood lymphocytes) 2ml is incubated in 24 well culture plates, and the action effect lymphocyte simultaneously, presses 2 * 10 with other a part of PBMC
6/ ml concentration dilution adds tumor antigen peptide 40ug/ml in RPMI 1640 substratum, 37 ℃ hatch 2 hours after, through 30GY
60The Co gammairradiation, centrifugal, flush away residue peptide, as cell antigen, it by effector cell: APC 1.3: 1 APC cell count, cell antigen is added above-mentioned effector cell's co-cultivation, after 24 hours, add IL-2 (Australian Ludwig Institute for Cancer Research provides) 25U/ml and continue to cultivate.Later on every 7 days, by the effector cell: cell antigen was that 1.3: 1 cell antigen quantity adds antigen presenting cell and stimulates among the effector cell 3 times again, detected the lethal effect of CTL in the 28th day.Killing experiments is undertaken by following: (1) adopts the on-radiation cell toxicant to analyze box, measures CTL and target cell and cultivates the lethal effect that back LDH releasing value detects CTL altogether.Operate according to the test kit recommended program.Used substratum is the no phenol red RPMI 1640 that contains 3%FCS, and 3 multiple holes are all established in every kind of reaction, measures the spontaneous releasing value of target cell, the maximum releasing value of target cell, the spontaneous releasing value of effector cell, volume correction value and substratum background value simultaneously.Use following formula and calculate lethal effect: lethal effect (%)=(the spontaneous releasing value of the spontaneous releasing value-target cell of experimental value-effector cell)/(the spontaneous releasing value of the maximum releasing value-target cell of target cell) * 100.(2) after mixed lymphocytes and target cell are cultivated 4 hours altogether, observe the morphological change of lymphocyte and target cell.After 28 days, peripheral blood lymphocytes has increased 28 times, the ratio of CD3 positive cell 15% (from 48% to 63%) that risen wherein, CTL ratio 18% (from 30% to 48%) that risen.As the effector cell: when target cell is 10: 1, what hatch is 51.4% from the lymphoblastic lethal effect of body to CTL to tumor antigen peptide (biochemical company limited is synthetic by the Shanghai gill), lethal effect to tumour antigen BJ-TSA-9 male tumour cell is 35.5%, and both are all apparently higher than to the lethal effect (1.84%) from the tumour cell of lymphoblastic lethal effect of body (13.6%) and tumour antigen BJ-TSA-9 feminine gender; As the effector cell: when target cell is 3.3: 1, CTL to tumor antigen peptide hatch be 53.5% from the lymphoblastic lethal effect of body, apparently higher than to from the lymphoblastic lethal effect of body (15.5%).
The tumour antigen Toplink of these presentation of results tumour antigens BJ-TSA-9 effectively induces the CTL with specific killing tumour cell from the PBMC of tumour patient, thereby strengthens the ability that tumour patient is removed tumour.
Embodiment 7, CTL cell are stimulated the detection of back secretion IFN γ ability by tumor antigen peptide
With reference to the experimental technique in the Chinese Medical Journal (81:1234,2001).Carry out the quantitative of IFN-γ with enzyme linked immunological spot detection method (ELISPOT).The flat nitrocellulose plate in 96 holes (available from French Millipore company), with anti-people IFN γ monoclonal antibody (be dissolved in the pH9.6 carbonate buffer solution, final concentration is 2ug/ml) bag quilt, 4 ℃ are spent the night; The 2nd day with after the phosphate buffered saline buffer that contains 0.05%Tween 20 (PBS) washing, with the RPMI RPMI-1640 room temperature lucifuge sealing that contains 10%AB serum 1 hour, with 0.05%Tween PBS washing, add again through 7 days inductive effector cells (effector cells, E) 5 * 10
4Individual/hole.After this experiment divides two groups to be carried out, and promptly effector cell and T2 groups of cells (E+T2), effector cell and T2 cell load tumor antigen peptide group (E+T2 tumor antigen peptide), does two multiple holes for every group.Simple T2 cell and the T2 cell that loaded the 10ug/ml tumor antigen peptide in serum-free RPMI 1640,37 ℃, 5%CO
2Hatched warp under the condition 2 hours
60Co gamma-rays 100GY irradiation, with after the unnecessary antigen peptide of serum-free RPMI 1640 flush awaies as irritation cell, with 1 * 10
5Individual/hole adds each effector cell hole; This reaction system in the RPMI RPMI-1640 of not factor-containing and serum, 37 ℃, 5%CO
2After hatching 18～20h under the condition, fully wash culture plate to remove residual cell with 0.05%TweenPBS: it is anti-to add the biotin labeled anti-people IFN γ of 0.2ug/ml two subsequently, hatches 2 hours in 37 ℃, washes plate; The Streptavidin 1ug/ml that adds alkali phosphatase enzyme mark again, lucifuge was hatched 1 hour under the room temperature; Wash plate, add substrate colour developing liquid, lucifuge colour developing 5 minutes, tap water flushing, termination reaction.After the question response plate dries, count every hole spot number of purple darkly down, obtain the mean value in two multiple holes in dissecting microscope.E+T2 tumor antigen peptide group spot number deducts E+T2 group spot number and is the special CTL cell frequency of tumour antigen.During ELISPOT detects, to produce the CD8 of IFN γ
+The frequency of T cell is an index, measures the respondent to tumour antigen BJ-TSA-9 respectively in the patient of expression of tumor tissue BJ-TSA-9mRNA, does not all detect corresponding specific immune among the patient that BJ-TSA-9mRNA expresses and replys and have at cancerous tissue.This experiment provides foundation for experiment in the clinical body of further using tumour antigen BJ-TSA-9 and antigen peptide treatment tumour.
Use tumor antigen protein matter provided by the invention and tumor antigen peptide the medicine of activation antineoplastic immune can be provided, diagnostic method of tumors can be provided.The tumor antigen protein matter among anti-the present invention or the antibody of tumor antigen peptide can be used for the preparation of affinity chromatography, cDNA library screening, immunology diagnosis or medicine.
Sequence table
Sequence length: 367
Topology: linearity
Sequence kind: peptide
The source:
Biological name: people (Homo sapiens)
Tissue types: cancerous lung tissue
Sequence signature:
The mark of feature: peptide
Location: 164～172
Sequence 1:
Met?Ser?Arg?Ser?Arg?His?Leu?Gly?Lys?Ile?Arg?Lys?Arg?Leu?Glu?Asp
1 5 10 15
Val?Lys?Ser?Gln?Trp?Val?Arg?Pro?Ala?Arg?Ala?Asp?Phe?Ser?Asp?Asn
20 25 30
Glu?Ser?Ala?Arg?Leu?Ala?Thr?Asp?Ala?Leu?Leu?Asp?Gly?Gly?Ser?Glu
35 40 45
Ala?Tyr?Trp?Arg?Val?Leu?Ser?Gln?Glu?Gly?Glu?Val?Asp?Phe?Leu?Ser
50 55 60
Ser?Val?Glu?Ala?Gln?Tyr?Ile?Gln?Ala?Gln?Ala?Arg?Glu?Pro?Pro?Cys
65 70 75 80
Pro?Pro?Asp?Thr?Leu?Gly?Gly?Ala?Glu?Ala?Gly?Pro?Lys?Gly?Leu?Asp
85 90 95
Ser?Ser?Ser?Leu?Gln?Ser?Gly?Thr?Tyr?Phe?Pro?Val?Ala?Ser?Glu?Gly
100 105 110
Ser?Glu?Pro?Ala?Leu?Leu?His?Ser?Trp?Ala?Ser?Ala?Glu?Lys?Pro?Tyr
115 120 125
Leu?Lys?Glu?Lys?Ser?Ser?Ala?Thr?Val?Tyr?Phe?Gln?Thr?Val?Lys?His
130 135 140
Asn?Asn?Ile?Arg?Asp?Leu?Val?Arg?Arg?Cys?Ile?Thr?Arg?Thr?Ser?Gln
145 150 155 160
Val?Leu?Val?Ile?Leu?Met?Asp?Val?Phe?Thr?Asp?Val?Glu?Ile?Phe?Cys
165 170 175
Asp?Ile?Leu?Glu?Ala?Ala?Asn?Lys?Arg?Gly?Val?Phe?Val?Cys?Val?Leu
180 185 190
Leu?Asp?Gln?Gly?Gly?Val?Lys?Leu?Phe?Gln?Glu?Met?Cys?Asp?Lys?Val
195 200 205
Gln?Ile?Ser?Asp?Ser?His?Leu?Lys?Asn?Ile?Ser?Ile?Arg?Ser?Val?Glu
210 215 220
Gly?Glu?Ile?Tyr?Cys?Ala?Lys?Ser?Gly?Arg?Lys?Phe?Thr?Gly?Gln?Ile
225 230 235 240
Arg?Glu?Lys?Phe?Ile?Ile?Ser?Asp?Trp?Arg?Phe?Val?Leu?Ser?Gly?Ser
245 250 255
Tyr?Ser?Phe?Thr?Trp?Leu?Cys?Gly?His?Val?His?Arg?Asn?Ile?Leu?Ser
260 265 270
Lys?Phe?Thr?Gly?Gln?Ala?Val?Glu?Leu?Phe?Asp?Glu?Glu?Phe?Arg?His
275 280 285
Leu?Tyr?Ala?Ser?Ser?Lys?Pro?Val?Met?Gly?Leu?Lys?Ser?Pro?Arg?Leu
290 295 300
Val?Ala?Pro?Val?Pro?Pro?Gly?Ala?Ala?Pro?Ala?Asn?Gly?Arg?Leu?Ser
305 310 315 320
Ser?Ser?Ser?Gly?Ser?Ala?Ser?Asp?Arg?Thr?Ser?Ser?Asn?Pro?Phe?Ser
325 330 335
Gly?Arg?Ser?Ala?Gly?Ser?His?Pro?Val?Pro?Glu?Ser?Lys?Gln?Asn?Lys
340 345 350
Thr?Lys?Thr?Lys?Lys?Gln?Thr?Thr?Leu?Trp?Phe?Leu?Met?Ala?Phe
355 360 365
Sequence length: 1936
Chain: two strands
Topology: linearity
Sequence kind: cDNA to mRNA
Hypothetical sequence: do not have
Antisense: do not have
Origin:
Biological name: people (Homo sapiens)
Tissue types: cancerous lung tissue
Sequence signature:
The expression mark of feature: 5 ' UTR
Location: 1..254
The expression mark of feature: CDS
Location: 256..1358
The expression mark of feature: 3 ' UTR
Location: 1359..1936
Sequence 2:
ccagcgccac?tgtgtacttc?cagaccgtca?agcacaacaa?catcagagac?ctcgtccgcc 60
gctgcatcac?ccggactaat?tgctcaggac?agcggtaaat?cacttcttgg?aggtgccctg 120
cacgctggtc?ctgggagcag?gcggcctccc?gggggtgcgg?gagccccact?cctccgtggt 180
gtgttccatt?tgcttcccac?atctggagga?gctgacgtgc?cagcctcccc?cagcaccacc 240
cagggacggg?aggcatgagc?cggtcaaggc?acctgggcaa?aatccggaag?cgtctggaag 300
atgtcaagag?ccagtgggtc?cggccagcca?gggctgactt?tagtgacaac?gagagtgccc 360
ggctggccac?ggacgccctc?ttggatgggg?gttctgaagc?ctactggcgg?gtgctcagcc 420
aggaaggcga?ggtggacttc?ttgtcctcgg?tggaggccca?gtacatccag?gcccaggcca 480
gggagccccc?gtgtccccca?gacaccctgg?gaggggcgga?agcaggccct?aagggactgg 540
actccagctc?cctacagtcc?ggcacctact?tccctgtggc?ctcagagggc?agcgagccgg 600
ccctactgca?cagctgggcc?tcagctgaga?agccctacct?gaaggaaaaa?tccagcgcca 660
ctgtgtactt?ccagaccgtc?aagcacaaca?acatcagaga?cctcgtccgc?cgctgcatca 720
cccggactag?ccaggtcctg?gtcatcctga?tggatgtgtt?cacggatgtg?gagatcttct 780
gtgacattct?agaggcagcc?aacaagcgtg?gggtgttcgt?ttgtgtgctc?ctggaccagg 840
gaggtgtgaa?gctcttccag?gagatgtgtg?acaaagtcca?gatctctgac?agtcacctca 900
agaacatttc?catccggagt?gtggaaggag?agatatactg?tgccaagtca?ggcaggaaat 960
tcactggcca?aatccgggag?aagttcatca?tctcggactg?gagatttgtc?ctgtctggat 1020
cttacagctt?cacctggctc?tgcggacacg?tgcaccggaa?catcctctcc?aagttcacag 1080
gccaggcggt?ggagctgttt?gacgaggagt?tccgccacct?ctacgcctcc?tccaagcctg 1140
tgatgggcct?gaagtccccg?cggctggtcg?cccccgtccc?gcccggagca?gccccggcca 1200
atggccgcct?tagcagcagc?agtggctccg?ccagtgaccg?cacgtcctcc?aaccccttca 1260
gcggccgctc?ggcaggcagc?caccccgttc?ctgaaagtaa?acaaaacaaa?acaaaaacaa 1320
aaaaacaaac?aacactttgg?ttcctgatgg?ctttctgaac?ccagccctga?ccttgttgtt 1380
tcacagctga?cggctgagat?gaggttagaa?tgactgggcc?cggctgaaca?ttccaaattg 1440
gatttcacca?tctgctgaga?aagtttaagg?aaggcaaagc?ttgccaggtc?acagaagctc 1500
ccaagcccag?ctttccaaag?gcctcagcct?gtgcctgtgt?cgagctcagt?cctgggagat 1560
aggggagaac?ctgcaggcag?gaacaagccc?ccctactcct?gaccaccctc?catcagcagt 1620
ctcccctccg?tggtcgtctt?tgttgacaaa?ggtgcagttt?ctcctctcct?gggcacctgt 1680
aacatgtgat?gcgctgcctg?ctgggaggtt?aggtcggggc?tgccccggcg?agtggagcat 1740
gagcagaacc?gccgagggtc?acttctgggc?agaagctttg?agagcctggg?tccaggttgc 1800
cacatagaag?cagctctcca?gttgaaaccc?tcctctgcca?gcctggggtc?ctaagcgatg 1860
agcagaatcc?cccactccca?ccccaccaac?ccacaatgga?tatgtagtga?gcaagaaata 1920
aacctttgtt?gtttaa 1936
SEQUENCE?LISTING
＜110〉Peking University
＜120〉a kind of tumor antigen protein matter and tumor antigen peptide
<130>FPI05129
<160>2
<170>Patentln?version?3.1
<210>1
<211>367
<212>PRT
<213>Homo?sapiens
<400>1
Met?Ser?Arg?Ser?Arg?His?Leu?Gly?Lys?Ile?Arg?Lys?Arg?Leu?Glu?Asp
1 5 10 15
Val?Lys?Ser?Gln?Trp?Val?Arg?Pro?Ala?Arg?Ala?Asp?Phe?Ser?Asp?Asn
20 25 30
Glu?Ser?Ala?Arg?Leu?Ala?Thr?Asp?Ala?Leu?Leu?Asp?Gly?Gly?Ser?Glu
35 40 45
Ala?Tyr?Trp?Arg?Val?Leu?Ser?Gln?Glu?Gly?Glu?Val?Asp?Phe?Leu?Ser
50 55 60
Ser?Val?Glu?Ala?Gln?Tyr?Ile?Gln?Ala?Gln?Ala?Arg?Glu?Pro?Pro?Cys
65 70 75 80
Pro?Pro?Asp?Thr?Leu?Gly?Gly?Ala?Glu?Ala?Gly?Pro?Lys?Gly?Leu?Asp
85 90 95
Ser?Ser?Ser?Leu?Gln?Ser?Gly?Thr?Tyr?Phe?Pro?Val?Ala?Ser?Glu?Gly
100 105 110
Ser?Glu?Pro?Ala?Leu?Leu?His?Ser?Trp?Ala?Ser?Ala?Glu?Lys?Pro?Tyr
115 120 125
Leu?Lys?Glu?Lys?Ser?Ser?Ala?Thr?Val?Tyr?Phe?Gln?Thr?Val?Lys?His
130 135 140
Asn?Asn?Ile?Arg?Asp?Leu?Val?Arg?Arg?Cys?Ile?Thr?Arg?Thr?Ser?Gln
145 150 155 160
Val?Leu?Val?Ile?Leu?Met?Asp?Val?Phe?Thr?Asp?Val?Glu?Ile?Phe?Cys
165 170 175
Asp?Ile?Leu?Glu?Ala?Ala?Asn?Lys?Arg?Gly?Val?Phe?Val?Cys?Val?Leu
180 185 190
Leu?Asp?Gln?Gly?Gly?Val?Lys?Leu?Phe?Gln?Glu?Met?Cys?Asp?Lys?Val
195 200 205
Gln?Ile?Ser?Asp?Ser?His?Leu?Lys?Asn?Ile?Ser?Ile?Arg?Ser?Val?Glu
210 215 220
Gly?Glu?Ile?Tyr?Cys?Ala?Lys?Ser?Gly?Arg?Lys?Phe?Thr?Gly?Gln?Ile
225 230 235 240
Arg?Glu?Lys?Phe?Ile?Ile?Ser?Asp?Trp?Arg?Phe?Val?Leu?Ser?Gly?Ser
245 250 255
Tyr?Ser?Phe?Thr?Trp?Leu?Cys?Gly?His?Val?His?Arg?Asn?Ile?Leu?Ser
260 265 270
Lys Phe Thr Gly Gln Ala Val Glu second eu Phe Asp Glu Glu Phe Arg His
275 280 285
Leu?Tyr?Ala?Ser?Ser?Lys?Pro?Val?Met?Gly?Leu?Lys?Ser?Pro?Arg?Leu
290 295 300
Val?Ala?Pro?Val?Pro?Pro?Gly?Ala?Ala?Pro?Ala?Asn?Gly?Arg?Leu?Ser
305 310 315 320
Ser?Ser?Ser?Gly?Ser?Ala?Ser?Asp?Arg?Thr?Ser?Ser?Asn?Pro?Phe?Ser
325 330 335
Gly?Arg?Ser?Ala?Gly?Ser?His?Pro?Val?Pro?Glu?Ser?Lys?Gln?Asn?Lys
340 345 350
Thr?Lys?Thr?Lys?Lys?Gln?Thr?Thr?Leu?Trp?Phe?Leu?Met?Ala?Phe
355 360 365
<210>2
<211>1936
<212>DNA
<213>Homo?sapiens
<400>2
ccagcgccac?tgtgtacttc?cagaccgtca?agcacaacaa?catcagagac?ctcgtccgcc 60
gctgcatcac?ccggactaat?tgctcaggac?agcggtaaat?cacttcttgg?aggtgccctg 120
cacgctggtc?ctgggagcag?gcggcctccc?gggggtgcgg?gagccccact?cctccgtggt 180
gtgttccatt?tgcttcccac?atctggagga?gctgacgtgc?cagcctcccc?cagcaccacc 240
cagggacggg?aggcatgagc?cggtcaaggc?acctgggcaa?aatccggaag?egtctggaag 300
atgtcaagag?ccagtgggtc?cggccagcca?gggctgactt?tagtgacaac?gagagtgccc 360
ggctggccac?ggacgccctc?ttggatgggg?gttctgaagc?ctactggcgg?gtgctcagcc 420
aggaaggcga?ggtggacttc?ttgtcctcgg?tggaggccca?gtacatccag?gcccaggcca 480
gggagccccc?gtgtccccca?gacaccctgg?gaggggcgga?agcaggccct?aagggactgg 540
actccagctc?cctacagtcc?ggcacctact?tccctgtggc?ctcagagggc?agcgagccgg 600
ccctactgca?cagctgggcc?tcagctgaga?agccctacct?gaaggaaaaa?tccagcgcca 660
ctgtgtactt?ccagaccgtc?aagcacaaca?acatcagaga?cctcgtccgc?cgctgcatca 720
cccggactag?ccaggtcctg?gtcatcctga?tggatgtgtt?cacggatgtg?gagatcttct 780
gtgacattct?agaggcagcc?aacaagcgtg?gggtgttcgt?ttgtgtgctc?ctggaccagg 840
gaggtgtgaa?gctcttccag?gagatgtgtg?acaaagtcca?gatctctgac?agtcacctca 900
agaacatttc?catccggagt?gtggaaggag?agatatactg?tgccaagtca?ggcaggaaat 960
tcactggcca?aatccgggag?aagttcatca?tctcggactg?gagatttgtc?ctgtctggat 1020
cttacagctt?cacctggctc?tgcggacacg?tgcaccggaa?catcctctcc?aagttcacag 1080
gccaggcggt?ggagctgttt?gacgaggagt?tccgccacct?ctacgcctcc?tccaagcctg 1140
tgatgggcct?gaagtccccg?cggctggtcg?cccccgtccc?gcccggagca?gccccggcca 1200
atggccgcct?tagcagcagc?agtggctccg?ccagtgaccg?cacgtcctcc?aaccccttca 1260
gcggccgctc?ggcaggcagc?caccccgttc?ctgaaagtaa?acaaaacaaa?acaaaaacaa 1320
aaaaacaaac?aacactttgg?ttcctgatgg?ctttctgaac?ccagccctga?ccttgttgtt 1380
tcacagctga?cggctgagat?gaggttagaa?tgactgggcc?cggctgaaca?ttccaaattg 1440
gatttcacca?tctgctgaga?aagtttaagg?aaggcaaagc?ttgccaggtc?acagaagctc 1500
ccaagcccag?ctttccaaag?gcctcagcct?gtgcctgtgt?cgagctcagt?cctgggagat 1560
aggggagaac?ctgcaggcag?gaacaagccc?ccctactcct?gaccaccctc?catcagcagt 1620
ctcccctccg?tggtcgtctt?tgttgacaaa?ggtgcagttt?ctcctctcct?gggcacctgt 1680
aacatgtgat?gcgctgcctg?ctgggaggtt?aggtcggggc?tgccccggcg?agtggagcat 1740
gagcagaacc?gccgagggtc?acttctgggc?agaagctttg?agagcctggg?tccaggttgc 1800
cacatagaag?cagctctcca?gttgaaaccc?tcctctgcca?gcctggggtc?ctaagcgatg 1860
agcagaatcc?cccactccca?ccccaccaac?ccacaatgga?tatgtagtga?gcaagaaata 1920
aacctttgtt?gtttaa 1936
Claims (8)
1, a kind of tumor antigen protein matter, this protein is by decomposing, can produce the peptide fragment that combines with major histocompatibility complex (MHC)-I quasi-molecule, can be discerned by the T cell in the cell, and it has following (a) or (b) described aminoacid sequence:
(a) has the aminoacid sequence shown in the sequence 1;
(b) with the aminoacid sequence in (a) through the replacement of one or several amino-acid residue, disappearance or add the derived protein that sudden change is produced, and this derived protein has identical functions with (a) protein.
2, the described tumor antigen protein matter of a kind of claim 1 is as the application of tumour specific antigen.
3, the application of the described tumor antigen protein matter of a kind of claim 1 in preparation treatment lung-cancer medicament.
4, a kind of dna sequence dna, the described tumor antigen protein matter of its coding claim 1.
5, dna sequence dna as claimed in claim 4 is characterized in that: described dna sequence dna is to have the nucleotide sequence shown in the sequence 2, and its accession number in gene library is AF497803.
6, the described gene of a kind of claim 5 is as the application of tumour specific antigen gene.
7, the tumor antigen peptide of the peptide fragment same function that produced of the described tumor antigen protein matter of a kind of and claim 1, it has the 164th～the 172nd aminoacid sequence of aminoacid sequence in the sequence 1.
8, the application of the described tumor antigen peptide of a kind of claim 7 in preparation treatment lung-cancer medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100118165A CN100393745C (en) | 2005-05-27 | 2005-05-27 | Tumour antigen protein and tumour antigen peptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100118165A CN100393745C (en) | 2005-05-27 | 2005-05-27 | Tumour antigen protein and tumour antigen peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1869064A true CN1869064A (en) | 2006-11-29 |
| CN100393745C CN100393745C (en) | 2008-06-11 |
Family
ID=37442858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100118165A Expired - Fee Related CN100393745C (en) | 2005-05-27 | 2005-05-27 | Tumour antigen protein and tumour antigen peptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100393745C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10526389B2 (en) | 2015-04-24 | 2020-01-07 | Immatics Biotechnologies Gmbh | Peptides and combinations of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers |
| CN113416240A (en) * | 2020-04-09 | 2021-09-21 | 北京臻知医学科技有限责任公司 | Universal antigen peptide library and kit for inducing tumor specific immune response |
| CN113501863A (en) * | 2021-08-10 | 2021-10-15 | 清华大学深圳国际研究生院 | Mucin13 antagonistic polypeptide, derivative and application thereof |
-
2005
- 2005-05-27 CN CNB2005100118165A patent/CN100393745C/en not_active Expired - Fee Related
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10925948B2 (en) | 2015-04-24 | 2021-02-23 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers |
| US10550167B2 (en) | 2015-04-24 | 2020-02-04 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers |
| US10577402B2 (en) | 2015-04-24 | 2020-03-03 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers |
| US10662233B2 (en) | 2015-04-24 | 2020-05-26 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers |
| US10898559B2 (en) | 2015-04-24 | 2021-01-26 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers |
| US10898560B2 (en) | 2015-04-24 | 2021-01-26 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers |
| US10526389B2 (en) | 2015-04-24 | 2020-01-07 | Immatics Biotechnologies Gmbh | Peptides and combinations of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers |
| US11027002B2 (en) | 2015-04-24 | 2021-06-08 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers |
| US11071773B2 (en) | 2015-04-24 | 2021-07-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers |
| US11324812B2 (en) | 2015-04-24 | 2022-05-10 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers |
| CN113416240A (en) * | 2020-04-09 | 2021-09-21 | 北京臻知医学科技有限责任公司 | Universal antigen peptide library and kit for inducing tumor specific immune response |
| CN113416240B (en) * | 2020-04-09 | 2022-04-12 | 北京臻知医学科技有限责任公司 | Universal antigen peptide library and kit for inducing tumor specific immune response |
| CN113501863A (en) * | 2021-08-10 | 2021-10-15 | 清华大学深圳国际研究生院 | Mucin13 antagonistic polypeptide, derivative and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100393745C (en) | 2008-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1102213A (en) | Isolated peptides which form complexes with MHC molecule HLA-C-Clone 10 and uese thereof | |
| CN1209876A (en) | Isolated tyrosinase derived peptides and uses thereof | |
| CN1154144A (en) | Isolated, tyrosinase derived peptides and uses thereof | |
| CN1869064A (en) | Tumour antigen protein and tumour antigen peptide | |
| CN1334873A (en) | Tumor Antigen protein ART-1 and tumor antigen peptide thereof | |
| CN1274827C (en) | Cancer gene and its coded protein and special cell line | |
| CN1869066A (en) | Tumour antigen protein and tumour antigen peptide | |
| CN1548455A (en) | Tumor antigen protein and tumor antigen peptide | |
| CN1264423A (en) | Cytoxtoxic T lymphocytes | |
| CN1861190A (en) | Application of anion exchange protein 1 and gene used as target for preparing medicine to treat alimentary canal tumor | |
| CN1548457A (en) | Tumor antigen protein and tumor antigen peptide | |
| CN1661053A (en) | Relativity between gene of growth hormone 1 and essential hypertension | |
| CN1355208A (en) | Polypeptide-human basic transcription factor 2-9.9 and polynucleotide for coding it | |
| CN1661051A (en) | Relativity between gene of growth hormone 1 and essential hypertension | |
| CN1315393A (en) | Polypeptide-human ribosome S11 protein 12 and polynucleotide for coding it | |
| CN1393463A (en) | Polypeptide-accessory factor-15.84 and polynucleotide for coding it | |
| CN1322743A (en) | New polypeptide human ribosomal protein S4-10 and its encoding polynucleotides | |
| CN1355299A (en) | Polypeptide-human uracil diphosphate glycopyrophosphorylase 100.47 and polynucleotide for coding it | |
| CN1322821A (en) | New polypeptide human ubiquitin conjugated enzyme 13 and its encoding polynucleotides | |
| CN1632119A (en) | Human LSB gene sequence, encoded polypeptide thereof, preparation method and use therefor | |
| CN1807451A (en) | ZIBC gene and its coded protein and uses | |
| CN1315510A (en) | Polypeptide-human ubiquitin-binding enzyme 17 and polynucleotide for coding it | |
| CN1323827A (en) | New polypeptide-human transcriptional activation protein subunit 14 and polynucleotides for coding same | |
| CN1661050A (en) | Relativity between gene of growth hormone 1 and essential hypertension | |
| CN1315415A (en) | Polypeptide-human ubiquitin-conjugated enzyme 9 and polynucleotide for coding it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080611 Termination date: 20170527 |